

African Vaccine Manufacturing Accelerator (AVMA)

8 August 2024



What is AVMA?

- The African Union has set out an ambitious goal for 60% of the vaccines required by the continent to be manufactured locally by 2040. In response, Gavi launched the African Vaccine Manufacturing Accelerator (AVMA), a pioneering initiative developed in collaboration with partners.
- AVMA is a financing instrument established to make up to US\$ 1.2 billion available over ten years to accelerate commercially viable vaccine manufacturing in Africa.
- The instrument offers financial incentives for vaccine production within African Union Member States, by making payments available when manufacturers obtain WHO prequalification for AVMA Priority vaccines, known as a Milestone payment; and/or per-dose Accelerator payments, receivable upon delivering eligible doses following a competitively won UNICEF tender.
- Over its lifetime, AVMA aims to support at least 800 million doses manufactured in Africa, across at least three vaccine production technologies. Supported facilities are projected to be able to fill 700 million doses per year in case of a future pandemic.

Why is it important?

- The COVID-19 pandemic brought the strategic importance of access to vaccines and supply resilience into the public eye, and to the forefront of the minds of policymakers. No region felt the negative effects of COVID-19 vaccine inequity more than Africa, and no region stands to benefit more from sustainable growth in its vaccine manufacturing sector.
- At present, demand for vaccines in Africa is valued at over US\$ 1 billion annually, with this figure projected to grow along with the continent's population over the next several decades. Africa already accounts for around 20% of the world's population, yet the continent's vaccine industry provides only around 0.1% of global supply.
- New vaccine manufacturers in Africa face significantly higher startup costs than other global suppliers. Initial capital investment costs are estimated to be 50% higher, compounded by 40% higher labour and 20% higher operating costs. These high startup costs mean that the commercial sustainability required for ongoing supply security is unlikely to develop without complementary downstream incentives. AVMA therefore has two overarching objectives:
 - a sustainable African manufacturing base that contributes to healthy global vaccine markets; and
 - improved pandemic and outbreak vaccine supply resilience in Africa.

AVMA incentives

Milestone payment

- US\$ 25 million: any Gavi portfolio vaccine whose drug substance is manufactured in an African Union Member State on an AVMA Priority technology platform (i.e. mRNA or viral vector).
- US\$ 20 million: AVMA Priority vaccines whose drug substance is manufactured in an African Union Member State.
- US\$ 10 million: AVMA Priority vaccines for which only 'fill and finish' takes place in an African Union Member State.

Accelerator payment

- US\$ 0.50 per dose: any Gavi portfolio vaccine whose drug substance is manufactured in an African Union Member State on an AVMA Priority technology platform (i.e. mRNA or viral vector).
- US\$ 0.50 per dose: AVMA Priority vaccines whose drug substance is manufactured in an African Union Member State.
- US\$ 0.40 per dose: any other Gavi portfolio vaccine whose drug substance is manufactured in an African Union Member State.
- US\$ 0.30 per dose: any Gavi portfolio vaccine for which only 'fill and finish' takes place in an African Union Member State, up to a cap of US\$ 1.00 per vial.

AVMA Priority technology platforms:

- mRNA
- Viral vector

AVMA Priority vaccines:

- Oral cholera
- Malaria
- Measles-rubella (MR)
- Hexavalent (wP)
- Yellow fever
- Pneumococcal, Ebola, rotavirus (certain specific presentations and strain coverages only)



Scan to find out more

Supporting vaccine manufacturing in Africa.
Visit <https://www.gavi.org/avma>
Contact: media@gavi.org